BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
Bergen, Norway, 24 May 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the first quarter 2022. A briefing by BerGenBio's senior management team will take place at 10:00am CEST today via a webcast presentation, followed by a Q&A session. Please see below for details. Operational Highlights – first quarter 2022 (including post-period end) · Post-period end, business strategy update announced, focusing on two key indications; 1st line STK11m non-